Suppr超能文献

发病年龄:帕金森病预后的主要决定因素。

Age at onset: the major determinant of outcome in Parkinson's disease.

作者信息

Hely M A, Morris J G, Reid W G, O'Sullivan D J, Williamson P M, Broe G A, Adena M A

机构信息

Neurology Department, Westmead Hospital, Sydney, Australia.

出版信息

Acta Neurol Scand. 1995 Dec;92(6):455-63. doi: 10.1111/j.1600-0404.1995.tb00480.x.

Abstract

Factors at presentation which influenced the course of the disease and response to treatment were assessed in 125 de novo patients with Parkinson's disease. Ninety-eight patients were available for re-assessment at 5 years. Older patients presented earlier after the onset of symptoms, deteriorated more rapidly, and were significantly more likely to develop dementia and impairment of balance. Increasing age and symmetrical disease predicted the new appearance of imbalance. Age of onset did not predict dyskinesia or end of dose failure. A low tremor score at baseline and female gender were predictive of the early appearance of dyskinesia. Patients who experienced end of dose failure were taking a significantly higher dose of levodopa. Once dose and duration of treatment were corrected for, no baseline features were predictive of end of dose failure. The dose of levodopa at 5 years was positively correlated to baseline disease severity as measured by the Columbia score. We conclude that the age of onset of symptoms of Parkinson's disease is a major determinant of the course of the disease and response to treatment.

摘要

对125例帕金森病初发患者进行评估,以确定发病时影响疾病进程及治疗反应的因素。98例患者在5年后可进行重新评估。年龄较大的患者在症状出现后更早就诊,病情恶化更快,且更易出现痴呆和平衡障碍。年龄增长和疾病对称性预示着平衡障碍的新出现。发病年龄不能预测异动症或剂末失效。基线震颤评分较低和女性性别可预测异动症的早期出现。经历剂末失效的患者服用左旋多巴的剂量显著更高。一旦校正治疗剂量和疗程,无基线特征可预测剂末失效。5年时左旋多巴剂量与用哥伦比亚评分衡量的基线疾病严重程度呈正相关。我们得出结论,帕金森病症状的发病年龄是疾病进程及治疗反应的主要决定因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验